7 April 2017
Projektträger – zwischengeschaltetes Finanzinstitut
Financing of Novozymes' research, development and innovation (RDI) activities for the development of biological solutions, industrial enzymes and microorganisms
The project concerns the financing of RDI activities in Denmark for the period 2017-2018, for the development of biological solutions, industrial enzymes and microorganisms. The RDI activities included in the project will be implemented in alignment with the existing RDI streams.
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 100 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 232 million
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2014/25/EU), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2014/25/EU and Directive 92/13/EEC) as interpreted by the Court of Justice of the EU, with publication of tender notices in the Official Journal of the EU, as and where required.
Unterzeichnet - 17/08/2017